Purchase this article with an account.
T. Yilmaz, K. Quinones, R. Cervantes-Castañeda, C. S. Foster; Long-Term Outcomes of Intravitreal Bevacizumab in Patients With Refractory Uveitic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4407.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the long-term outcomes of intravitreal bevacizumab injection in patients with refractory uveitic macular edema.
Chart review of all patients with intraocular inflammation who received intravitreal bevacizumab for refractory macular edema and had at least 6 months of follow-up. Outcome measures included changes in visual acuity and central retinal thickness (CRT), as determined by optical coherence tomography (OCT).
A total of 29 patients (30 eyes) were identified. Of these, 21 (62%) were female. The mean age of the cohort was 56.6 years. The diagnoses included: anterior uveitis (n=7), intermediate uveitis (n=2), posterior uveitis (n=13), and panuveitis (n=8). Of these, 9 patients had an associated systemic condition, which included juvenile idiopathic arthritis, multiple sclerosis, sarcoidosis, systemic lupus erythematosus, and ulcerative colitis. Initial (pre-treatment) CRT values were less than 300 microns (µm) in 10 (33%) of the cases, between 300 and 400 µm in 7 (23%), and greater than 400 µm in 13 (44%) of cases. Six months after having the injection, CRT values were less than 300 microns (µm) in 16 (53%) of the cases, between 300 and 400 µm in 5 (17%), and greater than 400 µm in 9 (30%) of cases. At this same time point, 13 (43%) eyes achieved acuities equal to or better than 20/40, 10 (33%) eyes saw between 20/50 and 20/100, and 7 (24%) eyes saw less than 20/100. As determined by OCT measurements, there was a net improvement or stabilization in 22 (73%) of the patients. Visual acuity improved or remained stable in 23 (77%) of the subjects.
Intravitreal bevacizumab appears to be a useful agent for the long-term control of refractory uveitic macular edema.
This PDF is available to Subscribers Only